Alto Neuroscience (ANRO) risk factors, FY2025 10-K

Other

1. 01Summary of Selected Risk Factors Associated with Our Business

Risks Related to Our Limited Operating History, Financial Position, and Need for Capital

1. 02We are a clinical-stage biopharmaceutical company with a limited operating history and no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of product candidates and the prospects for our future viability76% rewritten
2. 03for our product candidates, we will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transitionNew
3. 04We have incurred substantial losses since our inception. We anticipate incurring substantial and increasing losses for the foreseeable future and may never achieve or maintain profitability
4. 05We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce, or terminate our product development or future commercialization efforts
5. 06The obligations from our license and asset acquisition agreements may cause dilution to our stockholders, may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations

Risks Related to Product Candidate Development and Commercialization

1. 07Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support the approval of our current or any future product candidates
2. 08may disagree with our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trialsNew
3. 09We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
4. 10We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines50% rewritten
5. 11these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of our product candidates, if approved by the FDA or other regulatory authoritiesNew
6. 12If we are unable to develop and obtain regulatory approval or clearance for the companion diagnostic tools needed to leverage our Platform, our business, financial condition, results of operations, and prospects could be materially and adversely affected
7. 13We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining, or fail to obtain, regulatory approval for our product candidates
8. 14Additional time may be required to obtain marketing authorizations for any of our product candidates that we develop as drug/device combination products
9. 15Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of our product candidates
10. 16Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
11. 17If we fail to develop and commercialize our current product candidates for additional indications or fail to discover, develop, and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired
12. 18If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayedNew
13. 19We may expend our resources to pursue a particular product candidate or indication and forgo the opportunity to capitalize on product candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success
14. 20Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
15. 21We may conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business
16. 22Even if our product candidates receive regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable53% rewritten

Risks Related to Our Business and Operations

1. 23We were founded with a mission to redefine neuropsychiatric drug development, a field that has seen very limited success. The ability to successfully develop drugs in this field is extremely difficult and is subject to a number of unique challenges
2. 24Our business depends on the success of our product candidates. If we are ultimately unable to successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed24% rewritten
3. 25We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business
4. 26We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
5. 27Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 28Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
7. 29Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could adversely affect our business, financial condition, results of operations, and prospects
8. 30security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services including clinical trials. For example, we have been the target of unsuccessful phishing attempts in the past, and expect such attempts will continue in the futureNew
9. 31Many of our operations are concentrated in California, and we or the third parties upon whom we depend may be adversely affected by a wildfire and earthquake or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
10. 32Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products may be smaller than we estimate
11. 33Our business could be adversely affected by the effects of health pandemics or epidemics, which could cause significant disruptions in our operations and those of our current or future CMOs, CROs, and other third parties upon whom we rely

Risks Related to Collaborations, Intellectual Property, and Related Agreements

1. 34products similar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely affectedNew
2. 35Issued patents covering our product candidates, or the method of use of our product candidates or associated companion diagnostics could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
3. 36We may not be successful in obtaining or maintaining necessary rights to third party patents for our product candidates through acquisitions and in-licenses66% rewritten
4. 37commercializing product candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements
5. 38We may form or seek collaborations or strategic alliances, enter into additional licensing arrangements or other business transactions in the future, and we may not realize the benefits of such transactions
6. 39We may not be able to protect our intellectual property rights throughout the world
7. 40Intellectual property rights do not necessarily address all potential threats to our competitive advantage
8. 41We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates
9. 42We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
10. 43Our product candidates licensed from various third parties may be subject to retained rights
11. 44Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
12. 45We may become subject to claims challenging the inventorship or ownership of our or our licensors’ patents and other intellectual property
13. 46Patent terms may be inadequate to protect our competitive position on products or product candidates for a sufficient amount of time
14. 47If we do not obtain patent term extension for our product candidate, our business may be materially harmed
15. 48Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of noncompliance with these requirements
16. 49If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
17. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
18. 51rights of third parties, and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark
19. 52We may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property

Risks Related to Our Reliance on Third Parties

1. 53If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture product candidates may increase and commercialization may be delayed39% rewritten
2. 54The operations of our suppliers that are located outside of the United States are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations, and prospects68% rewritten
3. 55cGMPs, and guidelines for the manufacturing of biopharmaceuticals used in clinical trials and, if approved, marketed products. Our CMOs may have limited experience in the manufacturing of cGMP batches of our productsNew
4. 56We may have conflicts with our current or future licensors or collaborators that could delay or prevent the development or commercialization of our product candidates
5. 57We have historically relied on an affiliated third party to provide certain business services and the replacement of such services could adversely affect our business operations
6. 58Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks Related to Government Regulation

1. 59The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products
2. 60Drug marketing and reimbursement regulations in the EU may materially affect our ability to market and receive coverage for our products in the EU member states
3. 61observations. Accordingly, we and others with which we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control
4. 62The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
5. 63The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
6. 64Ongoing healthcare legislative and regulatory reform measures may adversely affect our business, results of operations, and financial condition30% rewritten
7. 65Additional laws and regulations governing international operations could adversely affect our business, results of operations and financial condition55% rewritten

Risks Related to Ownership of Our Common Stock and Our Status as a Public Company

1. 66An active and liquid trading market for our common stock may not continue to develop or be sustained
2. 67Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance we may publicly provide, each of which may cause our stock price to fluctuate or decline
3. 68Our stock price may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of shares of our common stock
4. 69We are currently subject to and may be subject to additional future securities class action litigationNew
5. 70We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
6. 71Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
7. 72We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors35% rewritten
8. 73Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders
9. 74Sales of a substantial number of our common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock46% rewritten
10. 75We have broad discretion in the use of our cash and cash equivalents and may not use them effectively, which could affect our results of operations and cause our stock price to decline
11. 76Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management, and limit the market price of our common stock
12. 77Our ability to use our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited39% rewritten
13. 78attain profitability, we may be unable to use all or a material portion of our net operating losses and other tax attributes, which could adversely affect our future cash flows. As a result of the foregoing, we have a full valuation allowance for deferred tax assets, including our NOL carryforwardsNew
14. 79Recent and future changes to tax laws could materially adversely affect our company35% rewritten
15. 80Unstable economic and market conditions may have serious adverse consequences on our business, financial condition, and stock price
16. 81If securities or industry analysts do not publish research or reports about our business, or if they publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
17. 82We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
18. 83Failure to establish and maintain effective internal control over financial reporting could adversely affect our business and if investors lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be negatively affected
19. 84Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud